(Q37615535)

21 August 2017

1 reference

title

Oncolytic virus therapy for prostate cancer (English)

1 reference

21 August 2017

1 reference

1 reference

2

Yukio Homma

1 reference

21 August 2017

Hiroshi Fukuhara

1

1 reference

PubMed ID

19832925

21 August 2017

Tomoki Todo

series ordinal

3

1 reference

21 August 2017

13 October 2009

1 reference

International Journal of Urology

21 August 2017

1 reference

21 August 2017

17

1 reference

21 August 2017

20-30

1 reference

21 August 2017

1

1 reference

21 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic viruses driven by tumor-specific promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Viral based gene therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic herpes simplex virus type 1 and host immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Oncolytic viral therapies - the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Potent oncolytic activity of human enteroviruses against human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02383.X

10.1111/J.1442-2042.2009.02383.X

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19832925